

## Datasheet: MCA2200B

**BATCH NUMBER 152872**

|                      |                         |
|----------------------|-------------------------|
| <b>Description:</b>  | MOUSE ANTI C-MYC:Biotin |
| <b>Specificity:</b>  | C-MYC                   |
| <b>Format:</b>       | Biotin                  |
| <b>Product Type:</b> | Monoclonal Antibody     |
| <b>Clone:</b>        | 9E10                    |
| <b>Isotype:</b>      | IgG1                    |
| <b>Quantity:</b>     | 0.1 mg                  |

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

|                            | Yes | No | Not Determined | Suggested Dilution |
|----------------------------|-----|----|----------------|--------------------|
| Immunohistology - Frozen   | ▪   |    |                |                    |
| Immunohistology - Paraffin | ▪   |    |                |                    |
| ELISA                      | ▪   |    |                | 1/20 - 1/50        |
| Immunoprecipitation        |     |    | ▪              |                    |
| Western Blotting (1)       | ▪   |    |                |                    |

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems using appropriate negative/positive controls.

**(1)9E10 recognizes c-myc under non-reducing conditions**

|                                 |   |
|---------------------------------|---|
| <b>Target Species</b>           | Human   |
| <b>Species Cross Reactivity</b> | <p>Reacts with: Epitope tag</p> <p><b>N.B.</b> Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.</p> |
| <b>Product Form</b>             | Purified IgG conjugated to Biotin - liquid  |
| <b>Preparation</b>              | Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant   |

|                                       |   |
|---------------------------------------|---|
| <b>Buffer Solution</b>                | Phosphate buffered saline   |
| <b>Preservative Stabilisers</b>       | 0.09% Sodium Azide<br>1% Bovine Serum Albumin   |
| <b>Approx. Protein Concentrations</b> | IgG concentration 0.1 mg/ml   |
| <b>Immunogen</b>                      | Synthetic peptide sequence corresponding to the C-terminal region (residues 408-439) of human c-myc conjugated to keyhole limpet hemocyanin.  |
| <b>External Database Links</b>        | <p><b>UniProt:</b><br/> <a href="#">P01106</a>   <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b><br/> <a href="#">4609</a>   MYC   <a href="#">Related reagents</a></p>   |
| <b>Synonyms</b>                       | BHLHE39   |
| <b>RRID</b>                           | AB_323950   |
| <b>Fusion Partners</b>                | Spleen cells from immunised BALB/c mice were fused with cells of the SP2/0 myeloma cell line.   |
| <b>Specificity</b>                    | <p><b>Mouse anti c-myc antibody, clone 9E10</b> detects the p62<sup>c-myc</sup> proto-oncogene protein, which is involved in the regulation of the cell cycle and cell growth. C-myc is primarily located to the cell nucleus, but has also been shown to localized to the cytoplasm in several cell lines (<a href="#">Craig <i>et al.</i> 1993</a>). Overexpression of c-myc has been reported in a wide variety of human cancers (Nesbit <i>et al.</i> 1999).</p> <p>Mouse anti c-myc antibody, clone 9E10 recognizes the sequence EQKLISEEDL and may be used to detect proteins and peptides labelled with molecular tags containing this sequence (Hilpert <i>et al.</i> 2001).</p>                                  |
| <b>Flow Cytometry</b>                 | Use 10ul of the suggested working dilution to label 1x10 <sup>6</sup> cells in 100ul.   |
| <b>Immunohistology</b>                | This product does not require protein digestion pre-treatment of paraffin sections prior to staining This product does not require antigen retrieval using heat treatment prior to staining of paraffin sections.   |
| <b>References</b>                     | <ol style="list-style-type: none"> <li>1. Evan, G.I. <i>et al.</i> (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. <a href="#">Mol Cell Biol. 5 (12): 3610-6.</a></li> <li>2. Spandidos, D.A. <i>et al.</i> (1987) Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. <a href="#">Anticancer Res. 7 (6): 1299-304.</a></li> <li>3. Borodina, I. <i>et al.</i> (2010) Display of wasp venom allergens on the cell surface of <i>Saccharomyces cerevisiae</i>. <a href="#">Microb Cell Fact. 9: 74.</a></li> <li>4. Groeger, G. <i>et al.</i> (2007) Co-operative Cdc42 and Rho signalling mediates ephrinB-</li> </ol> |

- triggered endothelial cell retraction. [Biochem J. 404: 23-9.](#)
5. Head, B. *et al.* (2009) Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. [J Cell Biol. 187: 959-66.](#)
  6. Hilpert, K. *et al.* (2001) Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. [Protein Eng. 14: 803-6.](#)
  7. Gohlke, S. *et al.* (2017) *In Vitro* and *In Vivo* Studies on the Structural Organization of Chs3 from *Saccharomyces cerevisiae*. [Int J Mol Sci. 18 \(4\): pii: E702.](#)
  8. Gray, P. *et al.* (2010) Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling. [J Immunol. 184: 6359-66.](#)
  9. Duriseti, S. *et al.* (2010) Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. [J Biol Chem. 285: 26878-88.](#)
  10. Tan, P.H. *et al.* (2005) Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. [Blood. 106: 2936-43.](#)
  11. Wallace, S.W. *et al.* (2010) Cdc42 regulates apical junction formation in human bronchial epithelial cells through PAK4 and Par6B. [Mol Biol Cell. 21: 2996-3006.](#)
  12. Rowshanravan, B. *et al.* (2014) RasGAP mediates neuronal survival in *Drosophila* through direct regulation of Rab5-dependent endocytosis. [J Cell Sci. 127: 2849-61.](#)
  13. Taylor K *et al.* (2015) Nanocell targeting using engineered bispecific antibodies. [MAbs. 7 \(1\): 53-65.](#)
  14. Elders, R.C. *et al.* (2014) Recombinant canine IgE Fc and an IgE Fc-TRAIL fusion protein bind to neoplastic canine mast cells. [Vet Immunol Immunopathol. 159 \(1-2\): 29-40.](#)
  15. Sharkey, A.M. *et al.* (2015) Tissue-Specific Education of Decidual NK Cells. [J Immunol. 195 \(7\): 3026-32.](#)
  16. McGough, I.J. *et al.* (2014) Identification of molecular heterogeneity in SNX27-retromer-mediated endosome-to-plasma-membrane recycling. [J Cell Sci. 127 \(Pt 22\): 4940-53.](#)
  17. Frohnert, C. *et al.* (2014) Importin 7 and Nup358 promote nuclear import of the protein component of human telomerase. [PLoS One. 9 \(2\): e88887.](#)
  18. Hage, N. *et al.* (2015) Improved expression and purification of the *Helicobacter pylori* adhesin BabA through the incorporation of a hexa-lysine tag. [Protein Expr Purif. 106: 25-30.](#)
  19. Mann, J.K. & Park, S. (2015) Epitope-Specific Binder Design by Yeast Surface Display. [Methods Mol Biol. 1319: 143-54.](#)
  20. Paraskevopoulou, V. *et al.* (2019) Introduction of a C-terminal hexa-lysine tag increases thermal stability of the LacDiNAc binding adhesin (LabA) exodomain from *Helicobacter pylori*. [Protein Expr Purif. 163: 105446.](#)
  21. Lim, H.K. *et al.* (2010) Flow cytometric analysis of genetic FRET detectors containing variable substrate sequences. [Biotechnol Prog. 26 \(6\): 1765-71.](#)
  22. Walker, L.M. *et al.* (2009) Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library. [J Mol Biol. 389 \(2\): 365-75.](#)
  23. Matos, J. *et al.* (2013) Cell-cycle kinases coordinate the resolution of recombination intermediates with chromosome segregation. [Cell Rep. 4 \(1\): 76-86.](#)
  24. Paraskevopoulou, V. *et al.* (2020) Structural and binding characterization of the LacdiNAc-specific adhesin (LabA; HopD) exodomain from *Helicobacter pylori*. [Curr Res Struct Biol. 15 Dec \[Epub ahead of print\].](#)

25. Kalusche, S. *et al.* (2020) Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis? [Vaccines \(Basel\). 8 \(4\) Dec 13 \[Epub ahead of print\].](#)
26. Hollandsworth, H.M. *et al.* (2020) Fluorophore-conjugated *Helicobacter pylori* recombinant membrane protein (HopQ) labels primary colon cancer and metastases in orthotopic mouse models by binding CEA-related cell adhesion molecules. [Transl Oncol. 13 \(12\): 100857.](#)

---

|                        |   |
|------------------------|---|
| <b>Further Reading</b> | <p>1. Nesbit, C. <i>et al.</i> (1999) MYC oncogenes and human neoplastic disease. <a href="#">Oncogene. 18: 3004-16.</a></p> <p>2. Krauß, N. <i>et al.</i> (2008) The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops. <a href="#">Proteins. 73: 552-65.</a></p> |
|------------------------|---|

---

|                |  |
|----------------|--|
| <b>Storage</b> | <p>Store at +4°C or at -20°C if preferred.</p> <p>This product should be stored undiluted.</p> <p>Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.</p> |
|----------------|--|

---

|                  |                                 |
|------------------|---------------------------------|
| <b>Guarantee</b> | 12 months from date of despatch |
|------------------|---------------------------------|

---

|                                      |  |
|--------------------------------------|--|
| <b>Health And Safety Information</b> | <p>Material Safety Datasheet documentation #10041 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA2200B">https://www.bio-rad-antibodies.com/SDS/MCA2200B</a></p> <p>10041</p> |
|--------------------------------------|--|

---

|                   |                            |
|-------------------|----------------------------|
| <b>Regulatory</b> | For research purposes only |
|-------------------|----------------------------|

---

|                                  |   |                  |   |               |   |
|----------------------------------|---|------------------|---|---------------|---|
| <b>North &amp; South America</b> | Tel: +1 800 265 7376<br>Fax: +1 919 878 3751<br>Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a> | <b>Worldwide</b> | Tel: +44 (0)1865 852 700<br>Fax: +44 (0)1865 852 739<br>Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a> | <b>Europe</b> | Tel: +49 (0) 89 8090 95 21<br>Fax: +49 (0) 89 8090 95 50<br>Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a> |
|----------------------------------|---|------------------|---|---------------|---|

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)  
'M366336:200529'

**Printed on 04 Apr 2024**